Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Innoviva, Inc. - Common Stock (NQ:INVA)

17.25 +0.04 (+0.26%)
Streaming Delayed Price Updated: 1:46 PM EDT, Oct 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Innoviva, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Innoviva Announces Retirement of Board Chairman
From Innoviva, Inc.
Via Business Wire
Elon Musk Says US Intel Agencies Had Access To Twitter DMs, Alibaba's Ant IPO Might Actually See Light, Airbus Pushes Some 2024 Deliveries: Today's Top Stories
Benzinga Elon Musk Drops Bombshell: US Intel Agencies Were Reading Your Twitter DMs 
Via Benzinga
FDA's AdComm Panel Favors Innoviva's Drug For Multidrug-Resistant Bacterial Infections
 
Via Benzinga
Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee
From Innoviva, Inc.
Via Business Wire
What 4 Analyst Ratings Have To Say About Innoviva
 
Via Benzinga
Innoviva Earnings Perspective: Return On Capital Employed
 
Via Benzinga
Innoviva Stock Trading Halted Today
From Innoviva, Inc.
Via Business Wire
Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic
From Innoviva, Inc.
Via Business Wire
Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Four Undervalued Healthcare Stocks for 2023
These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc. 
Via MarketBeat
Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)
From Innoviva, Inc.
Via Business Wire
Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022
--- Presentations Reinforce Topline Safety and Efficacy Findings and Highlight Consistency between Clinical and Microbiological Endpoints 
From Entasis Therapeutics Holdings Inc.
Via GlobeNewswire
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022
Six abstracts selected for presentation, including three oral presentations 
From Entasis Therapeutics Holdings Inc.
Via GlobeNewswire
A Look Into Healthcare Sector Value Stocks
The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base... 
Via Benzinga
Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings
 
Via Benzinga
5 Value Stocks In The Healthcare Sector
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators... 
Via Benzinga
Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
3 No-Brainer Stocks Under $10 to Buy for September
Cash-rich investors have the flexibility to buy no-brainer penny stocks to boost overall returns in a risk-adverse environment. 
Via InvestorPlace
Innoviva Completes Acquisition of La Jolla Pharmaceutical
From Innoviva, Inc.
Via Business Wire
Innoviva's Return On Capital Employed Overview
Pulled from Benzinga Pro data, Innoviva (NASDAQ:INVA) showed a loss in earnings since Q1, totaling $21.37 million. Sales, on the other hand, increased by 20.17% to $108.22 million during Q2. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 108 companies set new 52-week lows. 
Via Benzinga
Innoviva: Q2 Earnings Insights
Innoviva (NASDAQ:INVA) reported its Q2 earnings results on Wednesday, July 27, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Innoviva missed estimated earnings... 
Via Benzinga
Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Overview Of Value Stocks In The Healthcare Sector
What is a Value Stock? 
Via Benzinga
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022
Upgrades 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests
 
Via Benzinga
Innoviva Sells 15% Economic Stake in Theravance Respiratory Company to Royalty Pharma for approximately $282 million plus full ownership of existing equity investments and the potential for $50 million milestone payment
From Innoviva, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.